ecancermedicalscience

Clinical Study

Repurposing drugs in oncology (ReDO)—Cimetidine as an anti-cancer agent

26 Nov 2014
Pan Pantziarka, Gauthier Bouche, Lydie Meheus, Vidula Sukhatme, Vikas P Sukhatme

Cimetidine, the first H2 receptor antagonist in widespread clinical use, has anti-cancer properties that have been elucidated in a broad range of pre-clinical and clinical studies for a number of different cancer types. These data are summarised and discussed in relation to a number of distinct mechanisms of action. Based on the evidence presented, it is proposed that cimetidine would synergise with a range of other drugs, including existing chemotherapeutics, and that further exploration of the potential of cimetidine as an anti-cancer therapeutic is warranted. Furthermore, there is compelling evidence that cimetidine administration during the peri-operative period may provide a survival benefit in some cancers. A number of possible combinations with other drugs are discussed in the supplementary material accompanying this paper.

Related Articles

Tooba Ali, Laraib Khan, Bilal Mazhar Qureshi, Asim Hafiz, Maria Tariq, Khurram Minhas, Nasir Ali, Ahmed Nadeem Abbasi
Solomon Kibudde, Awusi Kavuma, Bonny Abal, Moses Fredrick Katumba, Cissy Bangidde Namutale, Daniel Kanyike, Israel Luutu
Swasthik Upadhya, Sameer Rastogi, Adarsh Barwad, Shamim Ahmed Shamim, Dikhra Khan, Sudheer Arava, Vineeta Ojha, Akshit Kumar Ganesan Karthikeyan, Akshya Kumar Bisoi
Hani Shihadeh, Ahmad Yousef, Ahmad Al-Leimon, Hussein Abu-Rumman, Laith Kreshan
Motunrayo Oluwabukola Adekunle, Aisha Musa, Chioma Ginika, Chisom Nri-Ezedii, Uduak Offiong, Hauwa Yusuf, Peter Odion Ubuane, Adewunmi Oyesakin, Ijeoma Nnenna Diaku-Akinwumi, Adaorah Onyiaorah
Aditya Dhanawat, Debdeep Samaddar, Bhagyashri Jadhav, Atul Tiwari, Kunal Jobanputra, Arnav Tongaonkar, Minit Jalan Shah, Nandini Menon, Priyamvada Maitre, Mahendra Pal, Amandeep Arora, Aparna Ringe, Archi Agrawal, Santosh Menon, Gagan Prakash, Vedang Murthy, Vanita Noronha, Kumar Prabhash, Amit Joshi